Document is current

Article History

Received: 10 January 2023

Accepted: 4 August 2023

First Online: 18 September 2023

Declarations

:

: All patients provided written informed consent prior to enrollment, and the trial was registered under ClinicalTrials.gov as NCT03299946. The protocol was approved by the Institutional Review Board (IRB) at Johns Hopkins University under the number IRB00149350. All patients provided written informed consent prior to enrollment for the use of clinical and genomic data for research. The study conformed to the principles of the Helsinki Declaration.

: Not applicable.

: R.A.A. reports receiving a commercial research support from Bristol-Myers Squibb and is a consultant/advisory board member for Bristol-Myers Squibb, Merck, AstraZeneca, Incyte, and RAPT Therapeutics. E.M.J. reports other support from Abmeta, personal fees from Genocea, personal fees from Achilles, personal fees from DragonFly, personal fees from Candel Therapeutics, other support from the Parker Institute, grants and other support from Lustgarten, personal fees from Carta, grants and other support from Genentech, grants and other support from AstraZeneca, personal fees from NextCure, and grants and other support from Break Through Cancer outside of the submitted work. M.Y. reports receiving research grants from Incyte, Bristol-Myers Squibb, and Exelixis and is a consultant for AstraZeneca, Eisai, Exelixis, and Genentech. E.J.F. is on the Scientific Advisory Board of Viosera Therapeutics/Resistance Bio and is a consultant to Mestag Therapeutics. The remaining authors declare that they have no competing interests. Cabozantinib was supplied by Exelixis, and nivolumab was supplied by Bristol-Myers Squibb.